Refer to word document for this table

Slides:

Advertisements

Similar presentations

IMMUNOPHENOTYPING OF HEMATOPOIETIC PROGENITOR CELLS BY MULTIPARAMETER FLOW CYTOMETRY.

Advertisements

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Flow cytometry to evaluate vaccine-induced T cell responses: standardized analysis of large numbers of FCS files Stephen De Rosa, M.D. HVTN Laboratory.

CD44 PD-L1 FSC Human/Mouse Stromal Markers FSC DAPI FSC SSC FSC-W FSC-H SSC-W SSC-H Live cells Tumor cells CD44 - CD44 + Supplementary Figure S1. Gating.

Main Figures and Tables

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Suppl Figure 1 NSCLC OvCa A B

Supplementary Figure 2. Free floating tumorspheres expressed multiple stem cell markers such as CD133, Nestin, Sox2 and Tra1-80, as shown for hypoxic.

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

+ + A. Standard Isolation Method: B. New Isolation Method: c-kit SORT

MicroRNA-21 Negatively Regulates Treg Cells Through a TGF-β1/Smad-Independent Pathway in Patients with Coronary Heart Disease Cell Physiol Biochem 2015;37:

A All patients Arm A Arm B Deaths/patients 21/30 7/10 14/20

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;

Supplementary Figure S1

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor Preston E. Bratcher, Steven M. Rowe, Ginger.

“Analyses of Pre-therapy Peripheral Immunoscore and Response to

Supplementary Figure 2 Supplementary Figure 2. White blood cell differential count White blood cell (WBC) differential counts were analyzed from patients.

Supplemental Figure 1 Supplemental Figure 1: IL-10 production in positively or negatively selected B cells. B cells were isolated with un-touched (Untouched.

Volume 154, Issue 4, Pages e6 (March 2018)

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

A B Supplemental Figure 1 PBMC Cervical Cytobrush

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

Volume 16, Issue 2, Pages (July 2016)

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Flow Cytometry Journal of Investigative Dermatology

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

Figure S2 Gating strategy of AT2 cells based on EpCAM and MHCII

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

Meghan Bliss-Moreau, Cristian Coarfa, Preethi H

Supplemental Tables/Figures

Volume 153, Issue 5, Pages e2 (November 2017)

Forkhead box protein 3 demethylation is associated with tolerance induction in peanut- induced intestinal allergy Meiqin Wang, MD, PhD, Ivana V. Yang,

Supplementary Figure 1 FSC-A SSC-A HC UC CD

Flow cytometry analysis of HLA-B27 and HLA-B7 transduced cells.

Expression Diversity Adds Richness to T Cell Populations

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Supplemental Figure 1A Pt Pt Pre-treatment

Peptide ID# Pulsed to T2-A24 Cells

Immunophenotyping of lymphocyte subsets.

Flow cytometric characterization of γδ T cells in our patient demonstrates specific expansion of a homogeneous Vδ2+ T cell population. Flow cytometric.

Supplemental Digital Content 2 – Figure 1

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%

Supplemental Digital Content 3 – Figure 2

Molecular Therapy - Oncolytics

Matthew Charles Woodruff, Eui Ho Kim, Wei Luo, Bali Pulendran

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

HCT-15 HT-29 * Figure S1. Oxaliplatin treatment increases CD44high subpopulations in both HCT-15 and HT-29 cells. Flow.

Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Figure 1 Flu immunization–induced changes in the proportions and absolute numbers of T cells and their relevant subpopulations Flu immunization–induced.

CD4 expressing CD161 and CD8 expressing CD161int are preserved in CVID

Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell.

CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to mitogen. CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to.

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Molecular Therapy - Methods & Clinical Development

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Immunologic and pharmacokinetic studies.

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

Quantitative PCR (A) and Western blot (B) analyses for expression of CD133 and ALDH isoforms in CD133+ and CD133− cells sorted from HCC cell lines PLC8024.

Supplementary Figures

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Refer to word document for this table Supplementary Table 1: AEs amongst all patients treated on trial Refer to word document for this table

Seroreactivity (any timepoint) - Endpoint ELISA Supplemental Table 2: Number of patients in each cohort with any seroreactivity against the candidate antigens (HPV 16,18 E6 and E7) at (A) any timepoint following vaccination and (B) three months following final vaccination A Seroreactivity (any timepoint) - Endpoint ELISA Cohort 1 Cohort 2 All Patients HPV16 E6 3/5 (60.0%) 6/12 (50.0%) 9/17 (52.9%) HPV16 E7 8/12(66.7%) 11/17 (64.7%) HPV18 E6 1/5 (20.0%) 7/12 (58.3%) 8/17 (47.1%) HPV18 E7 5/5 (100%) 10/12 (83.3%) 15/17 (88.2%) Any Antigen 12/12 (100%) 17/17 (100%) B Seroreactivity (three months following final vaccination) - Endpoint ELISA Cohort 1 Cohort 2 All Patients HPV16 E6 1/4 (25.0%) 1/8 (12.5%) 2/12 (16.7%) HPV16 E7 2/4 (50.0%) 3/8 (37.5%) 5/12 (41.6%) HPV18 E6 2/8 (25.0%) 3/12 (25.0%) HPV18 E7 4/4 (100%) 5/8 (62.5%) 9/12 (75.0%) Any antigen

HPV16 Specific CD8+ T cells expressing activation markers and lytic proteins (% of total CD3+CD8+) Patient ID Flow Cytometry Output Pre MEDI0457 Post MEDI0457 Difference 01 CD137+GrzA+GrzB+Prf+ 0.0% CD69+GrzA+GrzB+Prf+ CD38+GrzA+GrzB+Prf+ 02 0.33% 0.68% 0.57% 03 0.17% -0.17% 0.30% -0.30% 05 0.24% 0.21% -0.21% 09 0.18% -0.18% 0.28% 1.12% 10 0.07% 0.52% 0.45% 1.16% 1.38% 11 13 0.08% -0.08% 0.86% 0.89% 0.03% 0.34% 0.50% 0.16% Supplemental Table 3: Flow cytometry output frequencies for HPV16 specific CD8+ T cells before and after treatment with MEDI0457

HPV18 Specific CD8+ T cells expressing activation markers and lytic proteins (% of total CD3+CD8+) Patient ID Flow Cytometry Output Pre MEDI0457 Post MEDI0457 Difference 01 CD137+GrzA+GrzB+Prf+ 0.11% 0.0% -0.11% CD69+GrzA+GrzB+Prf+ 0.32% -0.32% CD38+GrzA+GrzB+Prf+ 02 0.04% 0.14% 03 -0.04% 05 0.17% 0.35% 0.18% 0.34% 0.06% -0.28% 09 0.40% 1.33% 10 0.05% 0.24% 0.19% 0.83% 1.11% 11 0.29% -0.29% 13 0.07% 1.21% 1.03% Supplemental Table 4: Flow cytometry output frequencies for HPV18 specific CD8+ T cells before and after treatment with MEDI0457

Supplementary Figure S1A: Flow Cytometry Gating for assessment of CD3+ CD8+ cells SSC Dump Channel CD8 FSC CD3 CD3

Before Activation (Negative After Activation (Positive Supplementary Figure S1B: Differential expression of CD38, CD69 and CD137 on CD3+ CD8+ cells before and after activation Before Activation (Negative Control) After Activation (Positive Control) CD38 CD69 CD137